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Abstract: This report describes a patient with intravascular large B-cell lymphoma (IVLBCL) 
with central nervous system involvement at the time of diagnosis who achieved complete remis-
sion for over 5 years in response to therapy. The patient, a 71 year-old woman, was previously 
healthy with the exception of taking verapamil for paroxysmal supraventricular tachycardia. 
She had presented with pyrexia and gradually progressive anemia. Brain magnetic resonance 
imaging revealed an infarct-like lesion in the pons, although no paralysis was observed. She was 
diagnosed with IVLBCL on the basis of random skin biopsy. After eight cycles of rituximab 
plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy, abnormal labora-
tory data had normalized, and no pontine lesion was evident on magnetic resonance imaging 
without receiving any intrathecal chemotherapy. IVLBCL is associated with poor prognosis, 
particularly in patients with central nervous system involvement. Early initiation of rituximab 
plus cyclophosphamide, doxorubicin, vincristine, and prednisone therapy and drug interactions 
between anticancer agents and verapamil as a p-glycoprotein inhibitor were considered the pos-
sible reasons for favorable outcome in the present case.
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Introduction
Intravascular large B-cell lymphoma (IVLBCL) is a rare and aggressive variant of 
extranodal large B-cell lymphoma with frequent involvement of the central nervous 
system (CNS) characterized by proliferation of large lymphoma cells within the lumina 
of the small vessels.1 The lack of characteristic clinical symptoms and the absence of 
lymphadenopathy can make the diagnosis of IVLBCL quite difficult, and the prog-
nosis for patients with this disease is extremely poor.2 The recent use of random skin 
biopsies has enabled earlier diagnosis of IVLBCL.3 While the anti-CD20 monoclonal 
antibody, rituximab, can improve survival for patients with IVLBCL,4 those with CNS 
involvement still have poor outcomes.5 The present report describes the first reported 
case of a patient with IVLBCL who was diagnosed in the early phase by a random 
skin biopsy and who was successfully treated with rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone (R-CHOP) therapy without any intrathecal 
treatment.
Case presentation
A 71 year-old woman had intermittent pyrexia (.38°C) for 1 week in May 
2009. Her family doctor treated her with a course of antibiotics to no effect. OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Computed tomography (CT), cardiac ultrasonography, and 
tuberculosis skin test detected no abnormalities. General 
malaise gradually developed, and hemoglobin (Hb) level fell 
from 10.2 g/dL to 9.0 g/dL over 2 weeks. She was admit-
ted to our hospital as a case of fever of unknown origin. 
On admission, pyrexia was the only abnormality on vital   
signs. She was taking no medications other than verapamil and 
digoxin for paroxysmal supraventricular tachycardia. Meticu-
lous physical examination detected anemic conjunctivae and 
edema of the bilateral lower extremities. No skin lesions, 
palpable lymph nodes, or neurological abnormalities were 
evident. Laboratory findings showed anemia (Hb, 8.8 g/dL) 
and elevated levels of lactate dehydrogenase (454 IU/L) 
and soluble interleukin-2 receptor (sIL2-R, 6,030 U/mL). 
Commonly used autoantibodies and tumor markers for assess-
ment of collagen diseases and cancers were all negative. CT 
scan revealed no lymphadenopathy, hepatosplenomegaly, 
or abnormal lung lesions. Gallium scintigraphy showed no 
abnormal accumulations. Brain magnetic resonance imaging 
(MRI) revealed a non-enhancing, high-intensity area of 17 
mm in diameter in the pons on T2- and diffusion-weighted 
imaging (Figure 1A and B); however, no abnormal neuro-
logical signs were observed. Cerebrospinal fluid examination 
likewise found no abnormalities. Based on the high sIL2-R 
level, IVLBCL was suspected. A bone marrow biopsy showed 
a normocellular marrow with no apparent lymphoma cells. 
Genetic analysis of the bone marrow specimen showed no 
clonal rearrangement of T-cell receptor Cβ1 or the immu-
noglobulin heavy chain JH region gene. We took healthy-
appearing skin randomly from the forearm, lower abdomen, 
and thigh for biopsy although no skin lesions were observed. 
All specimens revealed large B lymphoma cells within small 
veins and capillaries of the subcutaneous fat tissues but not 
outside the vessels (Figure 2A and B). Immunohistochemical 
studies showed that lymphoma cells were positive for CD20 
(Figure 3), a B-cell marker, and negative for CD3, a T-cell 
marker. Based on these findings, a diagnosis of IVLBCL was 
made. The patient’s poor general condition required a less 
toxic regimen, thus conventional R-CHOP therapy, consist-
ing of rituximab (375 mg/m2), cyclophosphamide (750 mg/
m2), doxorubicin (50 mg/m2), vincristine (1.4 mg/m2), and 
prednisolone (60 mg/m2), was started within 1 month of initial 
symptoms. After the first lumbar puncture for spinal fluid 
examination, the patient did not accept repeating it due to its 
invasiveness. For this reason, we treated the patient without 
any intrathecal   treatment. After the first cycle of systemic che-
motherapy, the patient had resolution of fever and peripheral 
edema, as well as improvement in Hb, lactate dehydrogenase, 
and sIL2-R levels. After eight cycles of R-CHOP therapy, the 
pontine lesion had completely disappeared (Figure 4A and B). 
Therefore, the asymptomatic reversible pontine lesion was 
considered as IVLBCL involvement. During follow-up, the 
value of sIL2-R had been within reference range. Currently at 
5 years after diagnosis, the patient has been doing well with 
Figure 1 The image shows a 17 mm high intensity area in the pons on T2-weighted (A) 
and diffusion-weighted (B) magnetic resonance imaging (MRI) of the brain.
Figure 2 Pathological specimens.
Notes: ( A)  Skin  biopsy  specimen  taken  from  the  lower  abdomen  reveals 
proliferation  of  large  lymphoma  cells  filling  the  vessels  of  hypodermic  adipose 
tissue. (B) Numerous lymphoma cells with irregular nuclear contours and large 
nucleoli clustered are seen in small vessel lumens. Hematoxylin and eosin staining; 
magnification (A) ×40 (B) ×100.
Figure 3 Immunohistochemistry demonstrating positivity of intravascular lymphoma 
cells for CD20.
Note: Magnification ×100.OncoTargets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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IVLBCL with CNS lesion in complete remission for over 5 years
no recurrence and returned to work without any neurological 
disorders.
Discussion
The present report describe a case of IVLBCL with CNS 
involvement that achieved complete remission for at least 
5 years in response to R-CHOP therapy. Patients with 
IVLBCL with CNS involvement have a high risk of devel-
oping CNS recurrence and poor outcomes, even if they 
receive intensive chemotherapy like autologous stem cell 
transplantation.5 There is no reported case that had main-
tained complete remission for over 5 years.
Clinical manifestations of IVLBCL are known to differ 
between Asian and Western countries.4 In Western countries, 
IVLBCL often involves the skin and CNS. While IVLBCL in 
Asian countries tends to show only few skin lesions,6 random 
skin biopsy still appears useful to diagnose IVLBCL in Japan.3,7 
In the present case, biopsied specimens were taken from appar-
ently healthy skin. Even when biopsy is not easily available, 
in a case where IVLBCL is clinically suspected, for example, 
when the patient has an increased level of sIL2-R with or with-
out lymphadenopathy, it is advisable to include random skin 
biopsies in the initial work-up to facilitate early diagnosis.
Rituximab-containing chemotherapies appear to improve 
clinical outcomes for IVLBCL patients.4 Additionally, 
a retrospective analysis demonstrated that rituximab might 
reduce the risk of CNS recurrence in IVLBCL patients.5 
Those facts indicate that IVLBCL should be treated with 
regimens including rituximab. Although a few case reports 
showed that a patient with IVLBCL with pontine involve-
ment was successfully treated with a rituximab containing 
regimen,8,9 the treatment effect of rituximab against IVLBCL 
with CNS involvement has not been clarified.4,5 Previous 
reports proposed that patients with IVLBCL with CNS 
involvement should be treated with regimens similar to those 
used for primary or secondary CNS lymphoma,10 including 
agents showing higher bioavailability in the CNS such as 
methotrexate or cytarabine.11,12 Besides, a case report sug-
gested that intrathecal chemotherapy is a useful treatment for 
IVLBCL with CNS involvement.8 However, the results in this 
case suggest that R-CHOP can be effective for early IVLBCL 
with CNS lesions. In fact, the blood–brain barrier (BBB) is 
likely to block access of drugs to sites of infiltrative tumors; 
thus, the effectiveness of R-CHOP on CNS lymphomas is 
not promising.13 In that respect, as lymphoma cells must be 
present in vessels, drug efficacy for IVLBCL does not neces-
sarily reflect vascular permeability; however, some IVLBCL 
cases indicate that minimal extravascular infiltration around 
the involved vessels occurs in the course of the disease.14 
Therefore, early diagnosis and early initiation of R-CHOP 
may have contributed to the favorable response, despite CNS 
involvement, in the present case.
Regarding the drug metabolism, verapamil and all drugs 
contained in CHOP regimen are metabolized by liver enzyme 
cytochrome P 3A4 (CYP3A4). Due to this fact, it is worth 
considering that the metabolization of these drugs was 
affected by the drug–drug interaction, although it is difficult 
to analyze plasma drug concentrations retrospectively.
In the present case, the patient was using 80 mg/day 
of verapamil and 0.25 mg/day of digoxin for paroxysmal 
supraventricular tachycardia. Verapamil is a potent inhibitor 
of p-glycoprotein, which plays an important role in anticancer 
drug resistance in malignant lymphoma15 and limits the access 
of systemic drugs across the BBB.16 Digoxin is also a substrate 
of p-glycoprotein and might modulate BBB permeability to 
various drugs.17 In in vitro experiments in a previous report, 
inhibition of p-glycoprotein using 0.1 µM/L of verapamil 
resulted in reversal of p-glycoprotein-mediated doxorubicin 
and vincristine resistance in lymphoma cells.18 According to 
the manufacturer’s data sheet of verapamil, the Cmax (the maxi-
mum serum concentration of drug) of 80 mg of verapamil suf-
ficiently reaches 0.1 µM/L. In fact, a combinational treatment 
effect between verapamil and anticancer agents for lymphoma 
patients has been reported previously.15 Therefore, taking 
verapamil during chemotherapy might contribute to complete 
remission despite CNS involvement in the present case.
In conclusion, treatment strategies for IVLBCL with CNS 
involvement are still controversial. The patient showed a 
favorable outcome after early diagnosis and the chemotherapy 
with verapamil. The present case suggests that early initiation 
of therapy and chemotherapy combined with p-glycoprotein 
inhibitors play an important role in treatment of IVLBCL 
Figure 4 Magnetic resonance imaging (MRI) of the brain after receiving chemotherapy.
Notes: Pontine lesion on T2-weighted (A) and diffusion-weighted (B) MRI of the 
brain completely resolved after eight cycles of rituximab plus cyclophosphamide, 
doxorubicin, vincristine, and prednisone therapy.OncoTargets and Therapy
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with CNS involvement. Further retrospective investigation 
into the time of initiation of therapy and drug interaction 
between p-glycoprotein inhibitors and anticancer agents in 
IVLBCL patients is needed.
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